BNP PARIBAS ARBITRAGE/PUT/ELI LILLY & CO/900/0.01/20.09.24 | Market Closed - Borsa Italiana 04:04:59 2024-07-11 pm EDT | ||
| 0.286 EUR | 0.00% |
|
| Current month | -17.62% | ||
| 1 month | -46.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.332 | +18.36% |
| 24-07-10 | 0.2805 | -3.28% |
| 24-07-09 | 0.29 | -16.91% |
| 24-07-08 | 0.349 | -4.38% |
| 24-07-05 | 0.365 | -19.25% |
Real-time Borsa Italiana
Last update July 11, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P23KQ0 | |
| ISIN | NLBNPIT23KQ0 |
| Date issued | 2024-05-29 |
| Strike | 900 $ |
| Maturity | 2024-09-20 (71 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.064 € |
|---|---|
| Lowest since issue | 0.2605 € |
| Spread | 0.03 € |
| Spread % | 9.84% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Warrants
- P23KQ0 Warrant
